Get the Stockscreener App
0.731
6.88%
-0.054
After Hours:
.73
-0.001
-0.14%
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial - ACCESS Newswire
Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA - ACCESS Newswire
Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits - ACCESS Newswire
Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia - ACCESS Newswire
Adial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder - ACCESS Newswire
Adial Pharmaceuticals Receives Positive FDA Feedback on In Vitro Bridging Strategy for AD04 - Defense World
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland - ACCESS Newswire
Adial gets FDA nod for Phase 3 drug strategy By Investing.com - Investing.com Australia
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs - AOL
Adial gets FDA nod for Phase 3 drug strategy - Investing.com India
Adial Pharmaceuticals Receives Positive Response from FDA - GlobeNewswire
Adial Pharmaceuticals Receives FDA's Positive Feedback On AD04 In Vitro Bridging Strategy - Nasdaq
Adial Pharmaceuticals Advances AD04 with FDA Approval - TipRanks
Adial's Addiction Treatment Clears Critical FDA Hurdle Ahead of 2025 Phase 3 Trials - StockTitan
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder - Benzinga
Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City - ACCESS Newswire
Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare - ACCESS Newswire
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia - ACCESS Newswire
Adial Pharmaceuticals secures patent for genetic addiction treatment By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Granted New U.S. Patent Expanding - GlobeNewswire
Adial Pharmaceuticals Granted New U.S. Patent On Method To Identify Genetic Markers In Alcohol or Opioid-Related Disorders - Marketscreener.com
Adial Granted New U.S. Patent Expanding Genetic-Based Approach For Addiction Treatment - Nasdaq
Adial Pharmaceuticals secures patent for genetic addiction treatment - Investing.com
This Groundbreaking Patent Could Transform How We Treat AddictionHere's Why Genetics Matter - StockTitan
Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria - ACCESS Newswire
Adial Is Filling The Gap In Alcohol Use Disorder Treatment With Repurposed Drug - Citeline News & Insights
Adial Pharmaceuticals secures new patent for addiction treatment By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Significant Growth in Short Interest - Defense World
Adial Pharmaceuticals secures new patent for addiction treatment - Investing.com India
Adial Pharmaceuticals Awarded U.S. Patent For Genotype-Specific Treatment Of Opioid Disorders - Nasdaq
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - The Manila Times
Adial Pharmaceuticals Secures Patent for Genetically Targeted Treatment Methods in Addiction Therapy - Nasdaq
Revolutionary Patent Win: Adial's DNA-Guided Solution Takes On $35B Addiction Crisis - StockTitan
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - Yahoo Finance
Reddit (RDDT) Q4 Earnings: What To Expect - The Globe and Mail
Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments - ACCESS Newswire
Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries - ACCESS Newswire
Clinical Trials News Live Feed - StockTitan
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands - AOL
Adial completes key study for alcohol disorder drug - MSN
Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder - ACCESS Newswire
ADILAdial Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - The Manila Times
Adial completes key study for alcohol disorder drug By Investing.com - Investing.com UK
Adial Pharmaceuticals Announces Positive Clinical Study - GlobeNewswire
Game-Changing Alcohol Addiction Treatment Clears Critical FDA Hurdle - StockTitan
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):